Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386887

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL996
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386884

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL993
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 14/07/2015 15:36:20 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

518804

	registered interest
	date	18/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Funeral Payments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the impact of Health Education England’s demand-led approach to the assessment of the number of consultant posts needed in highly specialist fields such as clinical pharmacology.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL98
	answer	answer is ministerial correction date of answer 25/05/2016 answer text <p>It is Health Education England’s responsibility to ensure that there is sufficient future supply of staff, including those needed in specialist fields, to meet the workforce requirements of the English health system.</p><p> </p><p>The Workforce Plan is built upon the needs of local employers, providers, commissioners and other stakeholders who, as members of its Local Education Training Boards (LETBs), shape the thirteen local plans.</p><p> </p><p>The Workforce Plan is predominately an aggregate of the local LETB plans, but the final national plan is only agreed with the advice and input of its clinical advisory groups and Patients’ Advisory Forum, as well as the Royal Colleges and other stakeholders.</p> answering member printed Lord Prior of Brampton question first answered 25/05/2016 13:52:12 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

753291

	registered interest
	date	18/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government whether they intend to ensure that Clinical Commissioning Groups are notified when a paediatric audiology service does not meet the standards for Improving Quality in Physiological Services accreditation following an assessment visit.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL979
	answer	answer is ministerial correction date of answer 20/07/2017 answer text <p>The Improving Quality in Physiological Services (IQIPS) accreditation scheme is run by the United Kingdom Accreditation Service (UKAS). The process of accreditation provides an independent assessment that a service meets the accreditation standards.</p><p> </p><p>It is the responsibility of the service to ensure that they conform to the standard before application to UKAS for accreditation. There is a pre-registration process within the scheme that enables all services to be able to do an effective gap analysis so that they should be at a point of conforming to the standard on making an application to UKAS. If during an assessment mandatory findings are raised which show non-conformity to any part of the standard then the service agrees appropriate improvement actions with the UKAS team to rectify these and prevent re-occurrence.</p><p> </p><p>The UKAS team base their recommendation for accreditation on the findings raised relating to the conformity to the standard, risk and whether the agreed improvement actions are appropriate and can be achieved within a three month close-out period. Therefore any findings raised must be cleared by the organisation if a positive recommendation for accreditation is to be granted.</p><p> </p><p>In <em>Commissioning Services for People with Hearing Loss: A framework for clinical commissioning groups</em>, published in July 2016, NHS England strongly encourages clinical commissioning groups to expect providers to have completed the IQIPS self-assessment tool and applied for accreditation with UKAS, and achieve accreditation within the duration of their contract.</p><p> </p><p>UKAS are supporting the NHS England business objective to increase the use of accreditation, and information about those services which have achieved accreditation is not held by the Department or NHS England, but is publicly available on the UKAS website.</p><p> </p><p>Information on clinical contracts is not held centrally by NHS England.</p> answering member printed Baroness Chisholm of Owlpen grouped question UIN HL887 HL889 HL890 HL891 question first answered 20/07/2017 14:50:44 answering member 4330 label Biography information for Baroness Chisholm of Owlpen
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

518803

	registered interest
	date	18/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prime Minister: Ministerial Policy Advisers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure that NICE guidance is followed in the use of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL97
	answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>The National Institute for Health and Care Excellence has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection under the interventional procedure programme. This programme makes recommendations about the safety of the procedures and how well they work. However the guidance does not constitute a direction to National Health Service trusts to provide the interventions. Decisions about whether to provide a treatment are taken locally.</p> answering member printed Lord Prior of Brampton grouped question UIN HL94 question first answered 26/05/2016 16:29:01 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

753281

	registered interest
	date	18/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government whether they intend to introduce legislation to regulate (1) physician assistants in anaesthesia, (2) physicians' associates, (3) advance critical care practitioners, and (4) surgical care practitioners; and if so, when.
	tabling member printed	Baroness Finlay of Llandaff
	uin	HL969
	answer	answer is ministerial correction date of answer 21/07/2017 answer text <p>The Government is committed to supporting the development of a modern health and care workforce as part of the continuing drive to provide safe, accessible and high quality care for patients and service users.</p><p> </p><p>The extension of statutory regulation to currently unregulated groups will only be considered where there is a solid body of evidence demonstrating a level of risk to the public which cannot be addressed through other means of assurance, including Accredited Voluntary Registers.</p><p><br> As the Secretary of State announced in his speech to NHS Providers in November 2016, the Department is developing proposals for a public consultation to consider whether physician associates should be regulated.</p><p> </p><p> </p> answering member printed Baroness Chisholm of Owlpen question first answered 21/07/2017 09:27:44 answering member 4330 label Biography information for Baroness Chisholm of Owlpen
	tabling member	3609 label Biography information for Baroness Finlay of Llandaff

753280

	registered interest
	date	18/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government how many times a hospital doctor has been required to be present during a patient transfer to another NHS Trust in the last 12 months; in each case, what was (1) the medical specialty of the doctor involved, and (2) the grade of the doctor involved; and in how many of those cases was a hospital department left without a consultant available within 30 minutes as a result of that transfer.
	tabling member printed	Baroness Finlay of Llandaff
	uin	HL968
	answer	answer is ministerial correction date of answer 21/07/2017 answer text <p>The data requested are not held centrally. Trusts are responsible for staffing arrangements including for ensuring appropriate arrangements and for procedures concerning the transfer of patients to other hospitals.</p> answering member printed Baroness Chisholm of Owlpen question first answered 21/07/2017 09:26:57 answering member 4330 label Biography information for Baroness Chisholm of Owlpen
	tabling member	3609 label Biography information for Baroness Finlay of Llandaff

753272

	registered interest
	date	18/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government, further to the Written Answers by Lord O’Shaughnessy on 23 January (HL4387) and on 3 February (HL4841), whether the new data collection on extended access to general practice includes data on the number of days that general practices were continuously closed over the Christmas and New Year holidays 2016-17; if so, why the Written Answer on 23 January stated that the Department of Health does not hold that information; and if not, whether they intend to extend that data collection to such information.
	tabling member printed	Lord Birt
	uin	HL960
	answer	answer is ministerial correction date of answer 20/07/2017 answer text <p>The extended access data collection does not collect this information. There are no plans to extend the data collection to cover specific arrangements such as holiday cover. The data collection was agreed following negotiations between the General Practitioner Committee and NHS England, and any change or amendment to it would require further negotiation.</p> answering member printed Baroness Chisholm of Owlpen question first answered 20/07/2017 14:47:45 answering member 4330 label Biography information for Baroness Chisholm of Owlpen
	tabling member	2533 label Biography information for Lord Birt

518802

	registered interest
	date	18/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Burial and Cremation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the rate of uptake by the NHS of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL96
	answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection. NICE has recommended that the procedure is safe enough for use in the National Health Service, but no assessment of its cost effectiveness has been made by NICE.</p><p> </p><p>Data on the uptake by the NHS of faecal microbiota transplants in the treatment of recurrent <em>Clostridium difficile</em> is not collected centrally.</p> answering member printed Lord Prior of Brampton grouped question UIN HL95 question first answered 26/05/2016 16:25:27 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath